TY - JOUR T1 - Intensive glucose control did not prevent important complications in type 2 diabetes JF - Evidence Based Medicine JO - Evid Based Med SP - 168 LP - 169 DO - 10.1136/ebm.13.6.168 VL - 13 IS - 6 A2 - , Y1 - 2008/12/01 UR - http://ebm.bmj.com/content/13/6/168.abstract N2 - A PatelDr A Patel, University of Sydney, Sydney, New South Wales, Australia; apatel@george.org.auDesign:randomised controlled trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]).Allocation concealment:concealed.*Blinding:blinded (outcome adjudication committee).*Setting:215 centres in 20 countries in Asia, Australasia, Europe, and North America.Patients:11 140 patients ⩾55 years of age (mean age 66 y, 58% men) who had type 2 diabetes and a history of, or risk factors for, vascular disease. Patients requiring insulin were excluded.Intervention:intensive glucose control with gliclazide modified-release, 30–120 mg/d, and other non-sulfonylurea drugs as needed to achieve a target glycated haemoglobin concentration ⩽6.5% (n = 5571) or standard glucose control with drugs other than gliclazide (n = 5569).Outcomes:composite of macrovascular events (non-fatal myocardial infarction or stroke, or death from cardiovascular causes) and composite of microvascular events (new or worsening nephropathy [including macroalbuminuria] or retinopathy). Secondary outcomes included new-onset microalbuminuria and severe hypoglycaemia.Follow-up period:median 5 years. … ER -